Image 1 of 1
Image 1 of 1
Image 1 of 1
Image 1 of 1
Retatrutide is an investigational once-weekly triple-hormone-receptor-agonist injection currently being developed by Eli Lilly for chronic weight management, obesity, and metabolic conditions.
How It Works
Triple Agonist: Unlike older medications that target one or two pathways, it activates three distinct hormone receptors simultaneously:
GLP-1 (Glucagon-like peptide-1): Reduces appetite, increases feelings of fullness, and slows stomach emptying.
GIP (Glucose-dependent insulinotropic polypeptide): Enhances insulin secretion and improves nutrient metabolism.
Glucagon (GCG): Stimulates fat breakdown (lipolysis) and raises energy expenditure.
Administration: Designed as a once-weekly subcutaneous (under the skin) injection.
Retatrutide is an investigational once-weekly triple-hormone-receptor-agonist injection currently being developed by Eli Lilly for chronic weight management, obesity, and metabolic conditions.
How It Works
Triple Agonist: Unlike older medications that target one or two pathways, it activates three distinct hormone receptors simultaneously:
GLP-1 (Glucagon-like peptide-1): Reduces appetite, increases feelings of fullness, and slows stomach emptying.
GIP (Glucose-dependent insulinotropic polypeptide): Enhances insulin secretion and improves nutrient metabolism.
Glucagon (GCG): Stimulates fat breakdown (lipolysis) and raises energy expenditure.
Administration: Designed as a once-weekly subcutaneous (under the skin) injection.